Send to

Choose Destination
Diabetes Obes Metab. 2018 Feb;20(2):448-452. doi: 10.1111/dom.13071. Epub 2017 Sep 14.

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).

Author information

INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France.
Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Department of Endocrinology and Diabetes, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Department of Diabetes, Endocrinology and Clinical Pharmacology, Glasgow Royal Infirmary, Glasgow, UK.
Diabetes Reference Unit, Clinic University Hospital, Valencia, Spain.
Sanofi, Paris, France.
Diabetes and Endocrinology Center, Rockwood Clinic, Spokane, Washington.


In this post hoc analysis we compared glycaemic control and hypoglycaemia between insulin glargine 300 U/mL (Gla-300) and glargine 100 U/mL (Gla-100) administered once daily in people with type 2 diabetes (T2DM) from the EDITION 1 (basal plus mealtime insulin) and EDITION 2 (basal insulin plus oral antihyperglycaemic drugs) trials who were previously receiving twice-daily insulin. At randomization, 16.9% and 20.0% of people in EDITION 1 and 2, respectively, were receiving twice-daily basal insulin. Glycated haemoglobin change from baseline to Month 6 was similar over 6 months with Gla-300 or Gla-100 (least squares mean difference -0.01%; 95% confidence interval [CI] -0.27 to 0.24] in EDITION 1 and 0.16%; 95% CI -0.25 to 0.57, in EDITION 2). Participants previously receiving twice-daily insulin in EDITION 1 had a lower risk of confirmed (≤3.9 mmol/L [≤70 mg/dL]) or severe hypoglycaemia with Gla-300 vs Gla-100 at night (00:00-05:59 hours), but not at any time (24 hours); in EDITION 2 the risk was reduced at night and any time (24 hours). In conclusion, Gla-300 provided similar glycaemic control with less hypoglycaemia compared with Gla-100 in people with T2DM switching from twice-daily to once-daily basal insulin.


basal insulin; glycaemic control; hypoglycaemia; insulin analogues; phase III study; type 2 diabetes

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center